ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 162 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2018. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,280 | -10.7% | 21,714 | +26.7% | 0.00% | – |
| Q2 2023 | $23,819 | +4.5% | 17,136 | +19.5% | 0.00% | – |
| Q1 2023 | $22,797 | -90.4% | 14,338 | -62.2% | 0.00% | – |
| Q4 2022 | $236,291 | +242.5% | 37,928 | +249.9% | 0.00% | – |
| Q2 2022 | $69,000 | -89.2% | 10,840 | -52.3% | 0.00% | -100.0% |
| Q1 2021 | $637,000 | +111.6% | 22,721 | +96.5% | 0.00% | – |
| Q4 2020 | $301,000 | -9.1% | 11,560 | +30.0% | 0.00% | – |
| Q3 2020 | $331,000 | +29.8% | 8,893 | +79.1% | 0.00% | – |
| Q2 2020 | $255,000 | +7.6% | 4,965 | +24.9% | 0.00% | – |
| Q4 2019 | $237,000 | +0.9% | 3,975 | -21.4% | 0.00% | – |
| Q2 2019 | $235,000 | -20.9% | 5,060 | -24.5% | 0.00% | – |
| Q3 2018 | $297,000 | +23.2% | 6,699 | +28.8% | 0.00% | -100.0% |
| Q2 2017 | $241,000 | – | 5,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,818,835 | $59,618,000 | 21.09% |
| Bellevue Group AG | 4,519,164 | $95,580,000 | 0.93% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,713,176 | $36,234,000 | 0.84% |
| Rhenman & Partners Asset Management AB | 572,267 | $12,103,000 | 0.82% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 64,434 | $1,363,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $10,575,000 | 0.37% |
| EMC Capital Management | 27,566 | $583,000 | 0.33% |
| WASATCH ADVISORS LP | 3,766,935 | $79,671,000 | 0.32% |
| Avidity Partners Management LP | 400,000 | $8,460,000 | 0.23% |
| Cinctive Capital Management LP | 186,170 | $3,937,000 | 0.18% |